Top

Current Pain and Headache Reports

Published in:

29-06-2023 | Migraine | Episodic Migraine (S Parikh, Section Editor)

Episodic Migraine and Psychiatric Comorbidity: A Narrative Review of the Literature

Authors: Alexis George, Mia T. Minen

Published in: Current Pain and Headache Reports | Issue 9/2023

Abstract

Purpose of Review

We evaluate the evolving evidence of psychiatric comorbidities associated with episodic migraine. Utilizing recent research publications, we aim to assess traditional treatment option considerations and discuss recent and evolving non-pharmacologic treatment progress for episodic migraine and related psychiatric conditions.

Recent Findings

Recent findings indicate that episodic migraine is strongly linked to comorbid depression, anxiety, posttraumatic stress disorder, and sleep disorders. Not only do patients with episodic migraine have higher rates of psychiatric comorbidity, but a higher number of headache days reported is also strongly linked to an increased risk of developing a psychiatric disorder, indicating there may be a link between frequency and psychiatric comorbidity and that patients with high-frequency episodic migraine should be assessed for psychiatric comorbidity. Few migraine preventive medications have examined the effect of the medication on both migraine and psychiatric comorbidity though we discuss what has been reported in the literature. Non-pharmacologic-based treatments including behavioral therapies and mind–body interventions previously developed for psychiatric conditions, e.g., mindfulness-based CBT (MBCT), acceptance and commitment therapy (ACT), and mindfulness-based stress reduction (MBSR) therapy, have promising results for patients diagnosed with episodic migraine and may therefore be useful in treating migraine and comorbid psychiatric conditions.

Summary

Psychiatric comorbidity may affect the efficacy of the treatment of episodic migraine. Thus, we must assess for psychiatric comorbidities to inform better treatment plans for patients. Providing patients with episodic migraine with alternate modalities of treatment may help to improve patient-centered care and increase patients’ sense of self-efficacy.

Stovner LJ, et al. “The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates,” J. Headache Pain. 2022;23(1):34–022–01402–2. https://doi.org/10.1186/s10194-022-01402-2.

Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496–505. https://doi.org/10.1111/head.13281.CrossRefPubMed

The International Classification of Headache Disorders 3rd edition. Available: https://ichd-3.org/.

Buse DC, et al. Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American migraine prevalence and prevention (AMPP) study. Headache. 2020. https://doi.org/10.1111/head.13966.CrossRefPubMedPubMedCentral

Jedynak j, et al. “Shift from high-frequency to low-frequency episodic migraine in patients treated with galcanezumab: results from two global randomized clinical trials,” J. Headache Pain. 2021;22(1):48–021–01222-w. https://doi.org/10.1186/s10194-021-01222-w.

Buse DC, et al. “Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study,” J. Headache Pain. 2020;21(1):23–020–1084-y. https://doi.org/10.1186/s10194-020-1084-y.

Lee S, et al. “Differences in frontal lobe dysfunction in patients with episodic and chronic migraine.” J Clin Med. 2021;10(13):2779. https://doi.org/10.3390/jcm10132779.

Anonymous American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. (5th ed.) Arlington, VA: American Psychiatric Publishing, 2013.

Dresler T, et al. “Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications,” J. Headache Pain. 2019;20(1):51–019–0988-x. https://doi.org/10.1186/s10194-019-0988-x.

10.

Altamura C, et al. “Pathophysiological bases of comorbidity in migraine,” Front. Hum. Neurosci. 2021;15:640574. https://doi.org/10.3389/fnhum.2021.640574.

11.

Planchuelo-Gómez A, et al. Gray matter structural alterations in chronic and episodic migraine: a morphometric magnetic resonance imaging study. Pain Med. 2020;21(11):2997–3011.CrossRefPubMed

12.

Karimi L, et al. “The migraine-anxiety comorbidity among migraineurs: a systematic review,” Front. Neurol. 2021;11:613372. https://doi.org/10.3389/fneur.2020.613372.

13.

Adams AM, et al. The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–78. https://doi.org/10.1177/0333102414552532.CrossRefPubMedPubMedCentral

14.

Chu H, et al. Associations between depression/anxiety and headache frequency in migraineurs: a cross-sectional study. Headache. 2018;58(3):407–15. https://doi.org/10.1111/head.13215.CrossRefPubMed

15.

Giannini G, et al. “Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study,” J. Headache Pain. 2013;14(1):49–2377–14–49. https://doi.org/10.1186/1129-2377-14-49.

16.

Amiri P, et al. “Migraine: a review on its history, global epidemiology, risk factors, and comorbidities,” Front.Neurol. 2022;12:800605. https://doi.org/10.3389/fneur.2021.800605.

17.

Peterlin BL, Nijjar SS, Tietjen GE. Post-traumatic stress disorder and migraine: epidemiology, sex differences, and potential mechanisms. Headache. 2011;51(6):860–8.CrossRefPubMedPubMedCentral

18.

Bainomugisa CK, et al. “Using monozygotic twins to dissect common genes in posttraumatic stress disorder and migraine,” Front. Neurosci. 2021;15:678350. https://doi.org/10.3389/fnins.2021.678350.

19.

Rantanen O, Hollmen M, Bachour A. Migraine may disturb sleep perception during sleep onset: a retrospective data analysis. J Clin Sleep Med. 2022;18(9):2113–7. https://doi.org/10.5664/jcsm.9992.CrossRefPubMed

20.

Vgontzas A, et al. Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six-week prospective cohort study of patients with episodic migraine. Headache. 2021;61(5):727–33.CrossRefPubMedPubMedCentral

21.

Klenofsky B. et al. “Episodic migraine comorbidities: avoiding pitfalls and taking therapeutic opportunities,” Curr. Pain Headache Rep. 2019;23(1):1–019–0742–8. https://doi.org/10.1007/s11916-019-0742-8.

22.

Yin J, et al. Prevalence and association of lifestyle and medical-, psychiatric-, and pain-related comorbidities in patients with migraine: a cross-sectional study. Headache. 2021;61(5):715–26.CrossRefPubMed

23.

Tiseo C, et al. “Migraine and sleep disorders: a systematic review,” J. Headache Pain. 2020;21(1):126–020–01192–5. https://doi.org/10.1186/s10194-020-01192-5.

24.

Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):313–23. https://doi.org/10.1007/s13311-018-0621-8.CrossRefPubMedPubMedCentral

25.

Buse DC, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018;38(10):1622–31. https://doi.org/10.1177/0333102418789072.CrossRefPubMed

26.

Stovner LJ, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomized, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523–32. https://doi.org/10.1177/0333102413515348.CrossRefPubMed

27.

Boal AH, et al. Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders. Hypertension. 2016;68(5):1132–8. https://doi.org/10.1161/HYPERTENSIONAHA.116.08188.CrossRefPubMed

28.

Silberstein SD, et al. “Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society,” Neurology. 2012;78(17):1337–1345.

29.

Burch R. “Antidepressants for preventive treatment of migraine,” Curr. Treat. Options Neurol. 2019;21(4):18–019–0557–2. https://doi.org/10.1007/s11940-019-0557-2.

30.

Krymchantowski AV, da Cunha Jevoux C, Bigal ME. “Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders,” J Headache Pain. 2011;13:53–59.

31.

Parikh SK, Silberstein SD. Preventive treatment for episodic migraine. Neurol Clin. 2019;37(4):753–70. https://doi.org/10.1016/j.ncl.2019.07.004.CrossRefPubMed

32.

Ozyalcin SN, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45(2):144–52. https://doi.org/10.1111/j.1526-4610.2005.05029.x.CrossRefPubMed

33.

Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol. 2018. https://doi.org/10.1001/jamaneurol.2017.5144.CrossRefPubMedPubMedCentral

34.

Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–62. https://doi.org/10.1212/wnl.55.6.754.CrossRefPubMed

35.

Holroyd KA, et al. “Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial,” Bmj. 2010;341: c4871. https://doi.org/10.1136/bmj.c4871.

36.

Powers SW, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622–30. https://doi.org/10.1001/jama.2013.282533.CrossRefPubMedPubMedCentral

37.

Seng EK, et al. Does mindfulness-based cognitive therapy for migraine reduce migraine-related disability in people with episodic and chronic migraine? A phase 2b pilot randomized clinical trial. Headache. 2019;59(9):1448–67. https://doi.org/10.1111/head.13657.CrossRefPubMedPubMedCentral

38.

Grazzi L, et al. ACT for migraine: effect of acceptance and commitment therapy (ACT) for high-frequency episodic migraine without aura: preliminary data of a phase-II, multicentric, randomized, open-label study. Neurol Sci. 2019;40(Suppl 1):191–2. https://doi.org/10.1007/s10072-019-03802-w.CrossRefPubMed

39.

Burrowes SAB, et al. Enhanced mindfulness-based stress reduction in episodic migraine-effects on sleep quality, anxiety, stress, and depression: a secondary analysis of a randomized clinical trial. Pain. 2022;163(3):436–44. https://doi.org/10.1097/j.pain.0000000000002372.CrossRefPubMedPubMedCentral

40.

Seminowicz DA, et al. Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes. Pain. 2020;161(8):1837–46. https://doi.org/10.1097/j.pain.0000000000001860.CrossRefPubMedPubMedCentral

41.

Segal Z, Williams M, and Teasdale J. Mindfulness-based cognitive therapy for depression, first edition: a new approach to preventing relapse. (1st ed.) Guilford Publications, Inc. 2001.

42.

Seng EK, et al. Response to mindfulness-based cognitive therapy differs between chronic and episodic migraine. Neurol Clin Pract. 2021;11(3):194–205. https://doi.org/10.1212/CPJ.0000000000000984.CrossRefPubMedPubMedCentral

43.

Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med. 1985;8(2):163–90. https://doi.org/10.1007/BF00845519.CrossRefPubMed

44.

Kabat-Zinn J, et al. Mindfulness-based stress reduction (MBSR) authorized curriculum guide. University of Massachusetts Medical School: Center for Mindfulness in Medicine, Healthcare, and Society; 2017.

45.

Wells RE, et al. Effectiveness of mindfulness meditation vs headache education for adults with migraine: a randomized clinical trial. JAMA Intern Med. 2021;181(3):317–28. https://doi.org/10.1001/jamainternmed.2020.7090.CrossRefPubMed

46.

Spitzer RL, Kroenke K, Williams JBW. “A brief measure for assessing generalized anxiety disorder: the GAD-7,” Arch Intern Med. 2006;166(10):1092.

47.

Kroenke K, et al. “The PHQ-8 as a measure of current depression in the general population,”J Affect Disord. 2009;114(1):163.

48.

Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. https://doi.org/10.1046/j.1525-1497.2001.016009606.x.CrossRefPubMedPubMedCentral

49.

Pilkonis PA, Choi SW, Reise SP, et al. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment. 2011;18(3):263–83. https://doi.org/10.1177/1073191111411667.CrossRefPubMedPubMedCentral

50.

Juang KD, et al. “Use of the hospital anxiety and depression scale as a screening tool for patients with headache.” 1999;62(11):749–755.

51.

Beck AT, Steer RA, and Brown G. “Beck depression inventory–II (BDI-II),” Apa Psyctests. 1996.

52.

Baik SH, et al. Reliability and validity of the perceived stress scale-10 in Hispanic Americans with English or Spanish language preference. J Health Psychol. 2019;24(5):628–39. https://doi.org/10.1177/1359105316684938.CrossRefPubMed

53.

Bastien CH, Vallieres A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307. https://doi.org/10.1016/s1389-9457(00)00065-4.CrossRefPubMed

54.

Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7(4):524–32.CrossRef

55.

Simons JS, Gaher RM. “Distress tolerance scale (DTS),” Apa Psyctests, 2005.

56.

French DJ, et al. Perceived self-efficacy and headache-related disability. Headache. 2000;40(8):647–56. https://doi.org/10.1046/j.1526-4610.2000.040008647.x.CrossRefPubMed

57.

Speck RM, et al. Psychometric validation and meaningful within-patient change of the migraine-specific quality of life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache. 2021;61(3):511–26. https://doi.org/10.1111/head.14031.CrossRefPubMedPubMedCentral

58.

Stewart WF, et al. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20–8. https://doi.org/10.1212/wnl.56.suppl_1.s20.CrossRefPubMed

Title: Episodic Migraine and Psychiatric Comorbidity: A Narrative Review of the Literature
Authors: Alexis George
Mia T. Minen
Publication date: 29-06-2023
Publisher: Springer US
Keywords: Migraine
Headache
Mood Disorders
Affective Disorder
Anxiety
Published in: Current Pain and Headache Reports / Issue 9/2023
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-023-01123-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Episodic Migraine and Psychiatric Comorbidity: A Narrative Review of the Literature

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2023

The Exploration of Cannabis and Cannabinoid Therapies for Migraine

The Potential of Psychedelics for the Treatment of Episodic Migraine

Telemedicine in Headache Medicine: A Narrative Review

Utilization of Regional Anesthesia in the Electrophysiology Lab: A Narrative Review

A Multimodal Conservative Approach to Treating Migraine: A Physical Therapist’s Perspective

Acupuncture for Low Back Pain: Reevaluation of Systematic Reviews and Meta-analyses